Aspirin Improves Colorectal Cancer Outcomes
- What: The FDA approved Arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- When: Approved May 3, 2023, with data published September 18, 2025, in the New England Journal of Medicine.
- Why it Matters: RSV causes significant illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
RSV Vaccine Approved for Older Adults: A Breakthrough in respiratory Protection
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the advancement of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the united States. The virus weakens the respiratory system, making individuals more vulnerable to secondary infections and exacerbating existing conditions like chronic obstructive pulmonary disease (COPD) and heart failure.
The impact of RSV extends beyond individual health. Hospitalizations strain healthcare resources, particularly during peak RSV season – typically fall and winter.The economic burden associated with RSV-related illness is significant, encompassing medical costs, lost productivity, and caregiver time.
The Arexvy Vaccine: How It Works and Trial Results
Arexvy, developed by GSK, is a recombinant subunit vaccine containing a stabilized prefusion F protein. This protein is found on the surface of the RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of antibodies that can neutralize the virus and prevent infection. The vaccine does not use a live virus, making it safe for older adults with weakened immune systems.
The pivotal Phase 3 trial, published in the New England Journal of Medicine on September 18, 2025, involved over 12,600 adults aged 60 years and older. The results demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease (LRTD) – defined as illness requiring medical intervention – and 94.1% against severe LRTD. The study also showed a statistically significant reduction in hospitalization due to RSV, although the exact percentage varied depending on the analysis.
| Outcome | Vaccine Efficacy (%) |
|---|---|
| RSV-associated LRTD | 82.6 |
| Severe RSV-associated LRTD | 94.1 |
Safety Profile and Potential Side Effects
The Arexvy vaccine was generally well-tolerated in clinical trials. The most common side effects reported were local reactions at the injection site, such as pain, redness, and swelling. systemic side effects, including fatigue, muscle aches, and headache, were also reported, but were generally mild to moderate in severity. A small number of participants experienced more serious adverse events, including Guillain-Barré syndrome (GBS), a rare neurological disorder. However, the association between the vaccine and GBS remains under investigation, and the FDA steadfast that the benefits of the vaccine outweigh the risks.
It’s important to note that the trial data, as of September 18, 2025, does not provide long-term safety information. Ongoing surveillance will be crucial to monitor for any rare or delayed adverse events.
Who Should Get the RSV Vaccine?
<